Transplant Reports : Open Access
Open Access

Aplastic anemia; Graft failure; Cord blood transplantation; Alternate transplantation

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is a standard remedy for cases with moderate to severe aplastic anemia that are youthful and fit and have a suitable stock patron. In addition, allogeneic HSCT from an indispensable patron, similar as bone gist transplantation (BMT) or supplemental blood stem cell transplantation (PBSCT) from an unconnected patron is indicated in cases who fail to respond to immunosuppressive remedy. Although the issues of allogeneic HSCT for aplastic anemia have been perfecting, graft failure (GF) remains the gravest and most life- changing complication. Issues of alternate HSCT after GF have been reported by several investigators; still, utmost of those studies concentrated on BMT from a HLAmatched stock. Data on a alternate HSCT from an indispensable patron are limited. A large-scale study lately conducted by the European Society for Blood and Gist Transplantation (EBMT) reported a 5- time overall survival (zilches) of 57 after a alternate HSCT (BMT or PBSCT) from an unconnected patron [1, 2].

In the setting of GF after first HSCT from an indispensable patron, umbilical cord blood transplantation (UCBT) may be another possible remedial option, especially when critical transplantation is needed. The reported rate of successful neutrophil engraftment is 51 to 71 after UCBT for aplastic anemia as the first transplantation, lower than that associated with BMT from an unconnected patron 16, 20. The part of UCBT as a alternate HSCT after GF has yet to be estimated, still. In the present study, we delved issues of a alternate UCBT in cases who endured GF after a first allogeneic HSCT for aplastic anemia [3].

Material and Methods

Data collection

The primary end of this study was to estimate the issues of alternate UCBT for GF after allogeneic HSCT in adult cases with aplastic anemia.

Case and transplantation data were attained from the Transplant Registry Unified Management Program, a database of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (21). Cases with aplastic anemia progressed ≥ 16 times that passed UCBT as the alternate transplantation for GF after a first allogeneic HSCT were enrolled in the study. Among 689 cases who passed a first allogeneic HSCT (BMT, n = 543; PBSCT, n = 75; UCBT, n = 71) between 2002 and 2011, 117 cases developed GF (primary, n = 61; secondary, n = 56). Of these, 23 passed UCBT as the alternate transplantation, and 22 were evaluable after 1 case was barred because of missing data. All 22 cases had experienced allogeneic HSCT from an indispensable patron, including 14 with BMT from an unconnected patron and 8 with UCBT as the first HSCT, performing in GF (primary GF, n = 8; secondary GF, n = 14). This study was approved by the Data Management Committee of the Japan Society for Hematopoietic Cell Transplantation and by the Institutional Review Board of Tohoku University Hospital (Sendai, Japan) [4, 5].

HLA typing

In all cases, data on HLA- A and HLA- B antigens using standard serologic or low- resolution ways were available. In addition, data on HLA- A, - B, and- DRB1 alleles using high- resolution DNA ways were available in 19 cases. According to the current practice in Japan, the number of mismatches in HLA- A,- B, and- DR loci was determined grounded the serologic or low- resolution situations.

Discussion

Regarding the first HSCT for aplastic anemia, a recent analysis from the Japanese registry set up an zilches of 69 at 3 times after UCBT, significantly lower than that of 8/ 8- matched unconnected BMT(UBMT)(3- time OS, 73), but analogous to that of 7/8- or 6/ 8- matched UBMT(20). Among cases age 16 to 39 times, the 3- time OS after UCBT wasn't statistically different from that after 8/ 8- matched UBMT (20). These findings suggest that UCBT may be a respectable option for cases with aplastic anemia if a suitable unconnected patron isn't available or critical transplantation is demanded. GF is a major problem after UCBT and UBMT for aplastic anemia, still 20, and 25. The only effective treatment for GF is an alternate transplantation. In this study, our analyis of the issues of alternate UCBT showed that all cases endured GF after the first UCBT or UBMT [6, 7].

To date, no study has specifically estimated the issues of an alternate UCBT for GF in cases with aplastic anemia. In the present study, the accretive prevalence of neutrophil engraftment by day 60 after the alternate UCBT for aplastic anemia was45.5 and the 4- time OS was38.5. The reported prevalence of GF is high (14.4 to 43) indeed after a alternate transplantation from a stock patron. The recent EBMT study of alternate HSCTs in cases with aplastic anemia set up neutrophil engraftment rates of 86 with a stock patron and 83 with an unconnected patron. Still, when GF occurs after matched affiliated patron transplantation, retransplantation from the same stock patron can be performed incontinently. Again, cases with GF witnessing HSCT from an unconnected patron for the alternate transplantation aren't considered in critical condition. Thus, the background of cases witnessing an alternate transplantation from a stock patron and those doing so from an unconnected patron could differ. Infectionassociated death passed in 5 of 12 cases who achieved engraftment after the alternate UCBT. Specially, 6 cases developed a fungal infection after the alternate UCBT. Expansive prophylaxis for fungal infection might be critical in the high- threat situation of an alternate UCBT for cases with GF [8, 9].

TNC cure was significantly associated with the engraftment rate after UCBT. The EBMT study on first UCBT for aplastic anemia demonstrated the vital part of TNC cure (>3.9 × 107/ kg) on engraftment by day 60( 58 versus 33) and 3- time OS( 45 versus 18) ( 16). In the EBMT cohort, 34 of 71 cases developed GF after UCBT, and 12 of them passed an alternate HSCT( 8 UCBT and 4 affiliated mismatched transplantation), 2 of whom survived. In our cohort of cases who passed an alternate UCBT for GF, an advanced TNC cure (>2.4 × 107/ kg) showed a trend toward lesser engraftment. According to the recent literature on optimal practices in UCBT the cell cure could be considered inadequate in nearly one- half of the cases in our study; therefore, the vacuity and selection of an umbilical cord blood (UCB) unit with an optimal cell cure could ameliorate issues indeed in the setting of an alternate UCBT for GF. In this setting, the use of double UCB units several ways to expand hematopoietic grandfathers in UCB and haplo- cord transplantation could be promising options [10].

Acknowledgment

None

Conflict of Interest

None

1. Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A, et al. (2022) Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release 348:706-722.

Indexed at, Google Scholar, Crossref

2. Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 28: 102-113.

Indexed at, Google Scholar, Crossref

3. Yan K, Zhang J, Yin W, Harding JN, Ma F, et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. IScience 4: 104822.

Indexed at, Google Scholar, Crossref

4. Zhang W, Huang X (2022) Stem cell membrane-camouflaged targeted delivery system in tumor. Mater Today Bio 1: 100377.

Indexed at, Google Scholar, Crossref

5. Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm Sin B 12: 3215-3232.

Indexed at, Google Scholar, Crossref

6. Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 111: 363-372.

Indexed at, Google Scholar         Crossref

7. Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci 9:1088-1103.

Indexed at, Google Scholar, Crossref

8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9: 675-689.

Indexed at, Google Scholar, Crossref

9. Shin MJ, Park JY, Lee DH, Khang D (2021) Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis. Int J Nanomedicine 16: 8485-8507.

Indexed at, Google Scholar, Crossref

10. Vasanthan V, Hassanabad AF, Fedak PWM (2021) Commentary: Cell therapy for spinal regeneration-implications for recovery after complex aortic surgery. JTCVS Open 24: 45-46.

Indexed at, Google Scholar, Crossref